Aurobindo Pharma Limited announced the approval of an Abbreviated New Drug Application for doxazosin mesylate tablets to be marketed immediately. This expansion into the oral generic segment signals a strategic move that is likely to intensify competition and increase profitability within the alpha-blocker market.